Neuromeka뉴로메카
348340 · KOSDAQ · ₩348340 · 뉴로메카
₩18,040▲ ₩1,150 (6.81%)End-of-day · Oct 28, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | ₩19B | ₩25B | ₩14B | ₩9.8B |
| Cost of sales | ₩15B | ₩21B | ₩13B | ₩8.6B |
| Gross profit | ₩3.5B | ₩4.1B | ₩1.2B | ₩1.2B |
| Operating income | −₩15B | −₩19B | −₩15B | −₩7.8B |
| Net income | −₩22B | −₩17B | −₩18B | −₩8.2B |
| Net income to shareholders | −₩22B | −₩17B | −₩18B | −₩8.2B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total assets | ₩91B | ₩95B | ₩96B | ₩44B |
| Current assets | ₩38B | ₩42B | ₩56B | ₩39B |
| Cash and equivalents | ₩17B | ₩19B | ₩8.5B | ₩10B |
| Total liabilities | ₩77B | ₩84B | ₩72B | ₩4.1B |
| Current liabilities | ₩69B | ₩58B | ₩51B | ₩4B |
| Borrowings | ₩31B | ₩53B | ₩38B | ₩2B |
| Total equity | ₩14B | ₩11B | ₩24B | ₩40B |
| Shareholders' equity | ₩14B | ₩11B | ₩24B | ₩40B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Cash from operations | −₩11B | −₩22B | −₩12B | −₩8B |
| Capital spending | ₩3.1B | ₩14B | ₩30B | ₩3B |
| Free cash flow | −₩15B | −₩36B | −₩43B | −₩11B |
Consolidated where available. Amounts in won.
Also known as: Neuromeka / 뉴로메카 / 348340 / KRX:348340
Source: KRX statistical information